High incidence of hepatocellular carcinoma in ESRD patients: Caused by high hepatitis rate or 'uremia'? A population-based study

Japanese Journal of Clinical Oncology

Volumn 42, Issue 9, 2012, Pages 780-786

  Hwang, Jyh Chang ^a,b   Weng, Shih Feng ^a,b   Weng, Rhay Hung ^b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

End stage renal disease; Hepatitis; Hepatocellular carcinoma; Incidence; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; FOLLOW UP; GOUT; HAZARD RATIO; HEART FAILURE; HEMODIALYSIS; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; UREMIA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CARCINOMA, HEPATOCELLULAR; CHILD; CHILD, PRESCHOOL; COMORBIDITY; FEMALE; HEPATITIS, VIRAL, HUMAN; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; KIDNEY FAILURE, CHRONIC; LIVER NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; SEX DISTRIBUTION; SURVIVAL RATE; TAIWAN; UREMIA;

EID: 84865552011     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys100     Document Type: Article

References (27)

1. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999;354:93-9.
2. Kantor AF, Hoover RN, Kinlen LJ, McMullan MR, Fraumenti JF, Jr. Cancer in patients receiving long-term dialysis treatment. Am J Epidemiol 1987;126:370-6.
3. Port FK, Ragheb NE, Schwartz AG, Hawthorne VM. Neoplasms in dialysis patients: a population-based study. Am J Kidney Dis 1989;14:119-23.
4. Vamvakas S, Bahner U, Heidland A. Cancer in end-stage renal disease: potential factors involved. Am J Nephrol 1998;18:89-95.
5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
6. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91.
7. Lin HF, Li YH, Wang CH, Chou CL, Kuo DJ, Fang TC. Increased risk of cancer in chronic dialysis patients: a population-based cohort study in Taiwan. Nephrol Dial Transplant 2011;27:1585-90.
8. Liang JA, Sun LM, Yeh JJ, Sung FC, Chang SN, Kao CH. The association between malignancy and end-stage renal disease in Taiwan. Jpn J Clin Oncol 2011;41:752-7.
9. Huang JF, Chuang WL, Dai CY, et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? J Intern Med 2006;260:255-62.
10. Tsai MC, Kee KM, Chen YD, et al. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan. J Gastroenterol Hepatol 2007;22:92-8.
11. Henderson WA, Shankar R, Gill JM, et al. Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma. J Viral Hepat 2010;17:59-64.
12. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38.
13. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:S112-9.
14. Siagris D, Christofidou M, Triga K, et al. Occult hepatitis B virus infection in hemodialysis patients with chronic HCV infection. J Nephrol 2000;19:327-33.
15. Bréchot C, Degos F, Lugassy C, et al. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med 1985;312:270-6.
16. Fabrizi F, Lunghi G, Finazzi S, et al. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis 2001;38:1009-15.
17. Trevizoli JE, de Paula Menezes R, Ribeiro Velasco LF, et al. Hepatitis C is less aggressive in hemodialysis patients than in nonuremic patients. Clin J Am Soc Nephrol 2008;3:1385-90.
18. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002;36:3-10.
19. Aghakhani A, Banifazl M, Kalantar E, et al. Occult hepatitis B virus infection in hemodialysis patients with isolated hepatitis B core antibody: a multicenter study. Ther Apher Dial 2010;14:349-53.
20. Barril G, Castillo I, Arenas MD, et al. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 2008;19:2288-92.
21. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005;18:52-61.
22. Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis 2006;194:594-9.
23. Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999;85:2132-7.
24. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-50.
25. Chen DS. Hepatocellular carcinoma in Taiwan. Hepatol Res 2007;37:S101-5.
26. Hu KQ, Lee SM, Hu SX, Xia VW, Hillebrand DJ, Kyulo NL. Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function. Am J Gastroenterol 2005;100:2010-8.
27. Dinits-Pensy M, Forrest GN, Cross AS, Hise MK. The use of vaccines in adult patients with renal disease. Am J Kidney Dis 2005;46:997-1011.